Effect of enalapril on left ventricular diameters and exercise capacity in asymptomatic or mildly symptomatic patients with regurgitation secondary to mitral valve prolapse or rheumatic heart disease.
The effects of 12 months of therapy were evaluated in 47 mildly symptomatic patients with moderate to severe mitral valve regurgitation; 26 patients received enalapril and 21 received a placebo. Enalapril was associated with a significant reduction in left ventricular diameter and mitral regurgitation volume, with no evidence of change in systolic function indexes. However, enalapril did not hinder progressive aerobic impairment to effort.
Sampaio
Roney O
RO
Department of Valvular Heart Disease, University of São Paulo Medical School, São Paulo, Brazil. val_roney@incor.usp.br
Grinberg
Max
M
Leite
João J
JJ
Tarasoutchi
Flávio
F
Chalela
William A
WA
Izaki
Marisa
M
Spina
Guilherme S
GS
Rossi
Eduardo Giusti
EG
Mady
Charles
C
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004656:Enalapril / Q000494:pharmacology* / Q000627:therapeutic use; D017079:Exercise Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000150:complications*; D008945:Mitral Valve Prolapse / Q000150:complications*; D010919:Placebos; D012214:Rheumatic Heart Disease / Q000150:complications*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D020257:Ventricular Remodeling
D000806:Angiotensin-Converting Enzyme Inhibitors; D010919:Placebos; D004656:Enalapril